UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. ACAD | 0.00 |
UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:
ACAD) with a Buy and raises the price target from $45 to $49.